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Platelet engraftment failure is a serious complication
leading to poor overall survival and quality of life in stem cell
transplantation. Neutrophil engraftment failure is usually
associated with failure of platelet engraftment. Relapse of
underlying disease such as acute leukemia can delay platelet
recovery. Because both of these situations aremajor causes of
poor survival, effect of platelet engraftment on survival is not
obvious in patients after neutrophil engraftment without
relapse.
We analyzed platelet engraftment in unrelated BMT (UR-
BMT), related BMT (Rel-BMT), related PBSCT (Rel-PBSCT),
and CBT using transplant outcome database of Japan Society
for Hematopoietic Cell Transplantation. Platelet engraftment
was deﬁned by the ﬁrst of three successive days with a non-
transfused platelet count of greater than 20x109/L. We
excluded cases with neutrophil engraftment failure or
relapse before achieving platelet engraftment, because both
of them can cause delay of platelet recovery. The study
population consisted of 12,101 patients who underwent UR-
BMT (3,482), Rel-BMT (3,153), Rel-PBSCT (2,834), or CBT
(2,632) for AML, ALL, CML, and MDS. The percentage of
platelet recovery (platelet count > 20x109/L, without trans-
fusion) in UR-BMT, Rel-BMT, Rel-PBSCT, and CBT was 89%,
94%, 93%, and 84%, and the median days of recovery after
transplantation was 28, 24, 18, and 44 days, respectively.
Multivariate Cox proportional hazards regression analysis
revealed that advanced stage of disease and poor perfor-
mance status ( grade 2) were common risk factors for
platelet engraftment failure in the four donor sources. Lower
cell dose was a signiﬁcant risk factor in UR-BMT and CBT.
HLA-mismatched graft was also signiﬁcant in the trans-
plantation other than CBT. We analyzed 1 year overall
survival in patients alive with or without platelet engraft-
ment every 10 days from 20 days to 100 days after trans-
plantation. Patients without platelet recovery showed
signiﬁcant poor survival than those with the recovery (Log-
rank test, p<0.001) at every point except day 20 in CBT. The
estimated 1 year overall survival of patients alive at day 100
with or without platelet recovery is 79% vs 62% (UR-BMT),
81% vs 62% (Rel-BMT), 72% vs 57% (Rel-PBSCT), 77% vs 57%
(CBT), and the probability of eventually achieving platelet
count>20x109/L in patients without recovery at day 100 was
25%, 31%, 34%, and 44%, respectively. Multivariate analysis
conﬁrmed that platelet recovery was signiﬁcantly associated
with survival.
In conclusion, platelet engraftment predicted overall
survival even excluding neutrophil engraftment failure and
early relapse in BMT, related PBSCT, and CBT.23
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We compared overall survival for recipients of a single
UCB unit treated for hematological malignancy on the COBLT
Study (n¼191) conducted from 1999-2004 to BMT CTN 0501
(n¼113) conducted from 2006-2012. The BMT CTN 0501 is
sponsored by NHLBI and NCI and, COBLT was sponsored by
NHLBI. Overall survival at 1-year was the primary endpoint
for both trials. Eligibility for both trials was similar with
a minimum total nucleated cell dose (TNC) of 2.5x107/kg for
BMT CTN and 1x107/kg for COBLT and HLA match of 4/6 at
antigen level for HLA A and B and allele level for HLA DRB1.
All patients received TBI 1350 cGy and cyclophosphamide
120 mg/kg. Patients enrolled on COBLT also received equine
ATG 90 mg/kg and those on BMT CTN 0501 ﬂudarabine
75mg/m2 with GVHD prophylaxis consisting of cyclosporine/
methyl prednisone and cyclosporine/mycophenolatemofetil,
respectively. The distribution of patient performance scores,
diseases, TNC (median dose: 4.8 x 107/kg for BMT CTN 0501
and COBLT, 5. 1 x 107/kg) and CD34 dose of the UCB units
were similar. Compared to those on BMT CTN 0501, patients
on COBLT were slightly younger (median age: 8 vs. 10 years,
p¼0.0007), more likely to be in relapse at transplant (16% vs.
5%, p¼0.0002) and less likely to receive a 5-6/6 HLA-matched
unit (29% vs. 59%, p<0.0001). The 1-year, the probabilities of
overall survival were 57% (95% CI 50 e 64) on COBLT and 71%
(95% CI 62 e 79) on BMT CTN 0501 (p¼0.01). In multivariate
analysis, mortality risks were higher for patients enrolled on
COBLT compared to those on BMT CTN 0501 (HR 1.82, 95% CI
1.19 e 2.78, p¼0.006). Mortality risks were also higher in
non-Caucasians independent of clinical trial (HR 1.95, 95%
1.32 e 2.88, p¼0.0007). The primary causes of death on both
trials were similar except for higher incidence of primary
graft failure on COBLT. The most frequent causes of death in
both treatment groups were recurrent leukemia and GVHD.
In summary, survival was better for patients treated on BMT
CTN 0501. Although it is not possible to prove which factor(s)
played the greatest role, it is the “package” including
conditioning and GVHD prophylactic regimens, supportive
care, method of unit selection and transplantation period
combined that contributed to the improved survival
observed in recipients of a single UCB unit in BMT CTN 0501.
Together, these results suggest the BMT CTN 0501 treatment
plan represents the new standard by which treatment
modiﬁcations will be compared.24
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